Xu Jin, Hardin Heather, Zhang Ranran, Sundling Kaitlin, Buehler Darya, Lloyd Ricardo V
Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, 53792, USA.
Endocr Pathol. 2016 Dec;27(4):271-275. doi: 10.1007/s12022-016-9448-1.
Stage-specific embryonic antigen-1 (SSEA-1), also known as CD15, is a member of a cluster of differentiation antigens that have been identified in various normal tissues and in different types of cancers including papillary and medullary thyroid carcinoma. SSEA-1 may be expressed in normal stem cells and cancer stem-like cells. To evaluate the potential diagnostic and prognostic utility of SSEA-1 in thyroid tumors, we analyzed the expression of SSEA-1 in normal and neoplastic thyroid tissues by immunohistochemistry (IHC) using a tissue microarray with 158 different tissue cores. To evaluate the potential utility of SSEA-1 as a surface marker, we also assessed the expression of SSEA-1 in thyroid cell lines by flow cytometric analysis. SSEA-1 immunoreactivity was identified in malignant thyroid follicular epithelial cancers but not in the benign thyroid tissues. Anaplastic thyroid (ATC) (80 %) and conventional papillary thyroid carcinoma (PTC) (60.7 %) showed significantly higher percentage of cases that were SSEA-1 immunoreactive than follicular variant of papillary thyroid carcinoma (FVPTC) (20.6 %) and follicular carcinoma (FCA) (32.1 %). Flow cytometric analysis of cultured thyroid cell lines showed that a small subpopulation of ATC and PTC thyroid tumor cells had SSEA-1 immunoreactivity which may represent thyroid cancer stem-like cells. The ATC cells expressed more SSEA-1 immunoreactive cells than the PTC cell lines. Our findings suggest that expression of SSEA-1 immunoreactivity in thyroid neoplasms was associated with more aggressive thyroid carcinomas. SSEA-1 is a marker that detects malignant thyroid neoplasms in formalin-fixed paraffin-embedded thyroid tissue sections and may be a useful marker for thyroid cancer stem-like cells.
阶段特异性胚胎抗原-1(SSEA-1),也称为CD15,是一组分化抗原中的一员,这些抗原已在各种正常组织以及包括乳头状和髓样甲状腺癌在内的不同类型癌症中被鉴定出来。SSEA-1可能在正常干细胞和癌干细胞样细胞中表达。为了评估SSEA-1在甲状腺肿瘤中的潜在诊断和预后效用,我们使用包含158个不同组织芯的组织微阵列,通过免疫组织化学(IHC)分析了SSEA-1在正常和肿瘤性甲状腺组织中的表达。为了评估SSEA-1作为表面标志物的潜在效用,我们还通过流式细胞术分析评估了SSEA-1在甲状腺细胞系中的表达。在恶性甲状腺滤泡上皮癌中鉴定出SSEA-1免疫反应性,但在良性甲状腺组织中未鉴定出。间变性甲状腺癌(ATC)(80%)和传统乳头状甲状腺癌(PTC)(60.7%)显示SSEA-1免疫反应性阳性的病例百分比显著高于甲状腺乳头状癌滤泡变体(FVPTC)(20.6%)和滤泡癌(FCA)(32.1%)。对培养的甲状腺细胞系进行流式细胞术分析表明,一小部分ATC和PTC甲状腺肿瘤细胞具有SSEA-1免疫反应性,这可能代表甲状腺癌干细胞样细胞。ATC细胞比PTC细胞系表达更多的SSEA-1免疫反应性细胞。我们的研究结果表明,甲状腺肿瘤中SSEA-1免疫反应性的表达与侵袭性更强的甲状腺癌相关。SSEA-1是一种在福尔马林固定石蜡包埋的甲状腺组织切片中检测恶性甲状腺肿瘤的标志物,可能是甲状腺癌干细胞样细胞的有用标志物。